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Abstract
Background: In patients with high grade glioma, little is known regarding existence of naturally
occurring adaptive T cell reactivity against glioma-associated antigens (GAAs). In this report, we
characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with
anaplastic astrocytoma (AA) for over 12 years without recurrence.
Methods: Peripheral blood mononuclear cells (PBMCs) derived from the long term survivor with
AA were evaluated for the frequency, cytotoxic T lymphocyte (CTL) activity and differentiation
status of CD8+ cells recognizing GAA-derived epitopes as well as relative numbers of other
immune cell subsets. This patient's AA tissue was evaluated for expression of two GAAs EphA2
and interleukin-13 receptor α2 subunit (IL-13Rα2) by immunohistochemistry.
Results: The patient's tumor expressed both EphA2 and IL-13Rα2, and in vitro stimulated PBMC
demonstrated superior EphA2883–891 and IL-13Rα2345–353-specific CTL reactivity compared to
PBMC samples from two other patients with progressing malignant glioma. Unstimulated EphA2883–
891-reactive CD8+ T cells contained high numbers of CD45RA-/CCR7- late effector and CD45RA-/
CCR7+ central memory cells. Among other leukocyte subsets, elevated numbers of NK-T cells
were found.
Conclusion: To our knowledge, the current study is one of the first demonstrating the presence
of antigen-experienced, GAA-reactive CD8+ T cells in a patient who has survived with AA for over
12 years without recurrence. Further studies are warranted to determine whether the status of
GAA-reactive CD8+ T cells dictates survival of patients and/or response to therapeutic vaccines.
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Malignant gliomas are the most common type of primary
brain tumor, and a major unsolved public health problem
with more than 12,000 new cases diagnosed each year in
the United States [1]. World health organization (WHO)
grade IV glioblastoma multiforme (GBM) is the most
common and most malignant of the glial tumors with a
median survival of 15 months with the current standard
of care, including surgery, radiation therapy and chemo-
therapy [2]. Anaplastic gliomas (AGs) constitute a group
of WHO grade III primary brain tumors including ana-
plastic astrocytoma (AA), anaplastic oligodendroglioma
(AO) [3], anaplastic mixed oligoastrocytoma, and ana-
plastic ependymoma [4,5]. The prognosis for AGs is still
poor. Although AO with chromosome 1p/19q loss
respond relatively well to chemotherapy [6,7], median
survival for AA patients is approximately 3 years with the
multimodal treatment with surgery, radiation and chem-
otherapy [8].
For cancer-immunosurveillance, cytotoxic T lymphocytes
(CTLs) are the key effector cells responsible for immune-
mediated destruction of malignant tumors [9,10]. Immu-
notherapy strategies have been developed to bolster CTL
responses against defined tumor-associated antigens in
melanoma by antigen-specific vaccination [11,12] and
adoptive transfer of CTL [13]. With regard to spontaneous
occurrence of CTL responses in cancer patients, long-last-
ing T cell immune responses against tumor-associated
antigens have been well documented in other types of
tumors that are considered "immunogenic", such as
malignant melanoma [14,15]. However, it remains
unclear whether patients with malignant glioma can
spontaneously mount antigen-specific T cell responses
against glioma-associated antigens (GAAs). This may be at
least partially due to the short survival period of these
patients.
In addition to CTLs, innate immunity mediated by natural
killer (NK) cells and NK-T cells may play significant roles
in anti-tumor immunity [16]. Tumor-infiltration of NK
cells has been demonstrated to be of positive prognostic
values [17]. Further progress of cancer immunotherapy
will benefit from better understanding of both innate and
adoptive immune response to cancer.
In the current study, we obtained PBMC samples and
tumor tissues from a patient who was diagnosed with AA
longer than 12 years ago and has had no recurrences since
the initial biopsy, radiation therapy and chemotherapy.
As median survival for AA patients is approximately 3
years with the current standard therapy [8], these precious
samples have provided us with a unique and privileged
opportunity to determine whether this patient has
mounted spontaneous anti-glioma immune responses.
Furthermore, this patient is positive for human leukocyte
antigen (HLA)-A2, allowing us to characterize CD8+ T cell
immune response against well-characterized HLA-A2-
restricted GAA-epitopes, such as EphA2 883–891 [18] and
IL-13Rα 2 345–353 [19], both of which were expressed in
this patient's tumor. Our results suggest that this patient




This study was approved by the local ethical review board
of University of Pittsburgh. Three glioma patients signed
informed consent before blood samples were obtained.
We evaluated PBMC samples derived from the following
3 HLA-A2 patients with high grade glioma (Table 1).
Patient AA-1 is a 51-year old Caucasian female who pre-
sented with sensory seizure in 1994. Biopsy of her left
temporal Gadolinium (Gd)-enhancing mass at the Mayo
Clinic lead to pathological diagnosis of AA. She was sub-
Table 1: Clinical histories of glioma patients
Case ID GBM-1 AA-1 AO-1
Gender M F M
Age at the time of Dx 55 51 58
KPS at the time of Dx 70% 80% 60%
Symptoms Aphasia Seizure Hemi-paresis, seizure
Histology GBM AA AO
Time from Dx to PBMC sampling 24 mos 153 mos 82 mos
Tumor location Lt. hemisphere Lt. temporal lobe Lt. frontal lobe
Treatment Bx Bx Bx, cystic aspiration
FEBRT FEBRT FEBRT
TMZ/CPT-11 (7 cycles) BCNU/CDDP/VP-16 (4 cycles) PCV (3 cycles), TMZ
Time to progression from the Dx 3 mos No progression for 153 mos 12 mos
Current status of tumor Progressive disease No Gd-enhancing lesion Progressive disease
M; male, F; female, GBM; glioblastoma, AO; anaplastic oligoastrocytoma, mos; months, Bx; biopsy, Dx; diagnosis, KPS; Karnofsky performance 
status, FEBRT; fractionated external beam radiation therapy, Gd; Gadolinium, TMZ; temozolomide, PCV; procarbazine, lomustine and vincristine, 
CPT-11; irinotecan, BCNU; bischloroethylnitrosourea, CDDP; cisplatin, VP-16; etoposide.Page 2 of 11
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tion therapy (FEBRT) and 4 cycles of chemotherapy
consisting of BUNU (bischloroethylnitrosourea), cispla-
tin and etoposide. She demonstrated a complete disap-
pearance of the Gd-enhancing lesion on MRI, and to date,
has had no evidence of tumor recurrence based regular
follow-up MRI scans.
Patient GBM-1 is a 55-year old Caucasian male who pre-
sented with motor aphasia in 2005. MRI demonstrated
mulitfocally enhancing masses in his left hemisphere, and
biopsy in University of Pittsburgh revealed GBM. The
patient subsequently received FEBRT and concurrent
chemotherapy with temozolomide (TMZ), followed by
adjuvant chemotherapy using TMZ and CPT-11 for 7
cycles before progression was confirmed by MRI at 6
months after the biopsy.
The other patient AO-1 is a 58-year old Caucasian male
who presented with right hemi-paresis in 2000. Biopsy of
ring-enhanced cystic lesion in his left frontal lobe led to
pathological diagnosis of AO. Despite FEBRT and subse-
quent 3 cycles of chemotherapy with PCV, progression
was found at 1 year after the diagnosis. Although the
patient demonstrated partial response to the 2nd line
chemotherapy with TMZ, the Gd-enhancing lesion
remained as stable disease with continued TMZ therapy
when blood samples were drawn.
Cell lines
The SNB19 glioma cells were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS), 100 IU/mL
penicillin, 100 µg/mL streptomycin, and 10 mmol/L L-
glutamine (all reagents from Invitrogen, Carlsbad, CA)
[19]. The transporter associated with antigen processing-
deficient, HLA-2.1+ T2 cell line was maintained in RPMI
1640 (Invitrogen) supplemented with 10% FBS and 100
IU/mL penicillin, 100 µg/mL streptomycin, and 10
mmol/L L-glutamine (all reagents from Invitrogen) [19].
Immunohistochemical staining
Paraffin-embedded tissue sections (10 µm) were depar-
affinized in xylene and rehydrated in a series of ethanol/
PBS washes. Antigenicity was retrieved with modified cit-
rate solution (Dako) in a pressure cooker for 20 minutes.
Endogenous peroxidase was blocked by incubation in
3.0% hydrogen peroxide in PBS, and the nonspecific
binding of antibodies was blocked by incubation in
serum-free blocking solution (Dako) for 1 hour. The
slides were then incubated with anti-human EphA2 mon-
oclonal antibody (1:100; Ab 208, mIgG1, MedImmune)
or anti-human IL-13Rα2 polyclonal antibody (15 µg/ml;
AF146, gIgG, R&D) diluted in the same blocking solution
overnight at 4°C. The slides were incubated with goat
anti-mouse (1:200; Upstate Cell Signaling) or rabbit anti-
goat (1:200; Abcam) secondary antibodies for 1 hour at
room temperature. HRP labeling was visualized using
Vectastain's Nova Red kit. The sections were lightly coun-
terstained with Gill's hematoxylin.
Peptides
The synthetic peptides IL-13Rα2 (345–353, WLPFGFILI;
345-1A9V, ALPFGFILV), EphA2 (883–891, TLADFDPRV)
and Influenza M1 (58–66, GILGFVFTL) were synthesized
by N-(9-fluorenyl) methoxycarbonyl chemistry in the
University of Pittsburgh Peptide Synthesis Facility and
were >95% pure as indicated by analytic high-perform-
ance liquid chromatography and mass spectrometric anal-
ysis. Peptides were dissolved in PBS/10% DMSO at a
concentration of 2 mg/mL and stored at -20°C until use.
HLA-A2/peptide tetramer staining
Phycoerythrin (PE)-conjugated human leukocyte antigen
(HLA)-A*0201/ALPFGFILV tetramer (IL-13R2-tetramer)
and PE-conjugated HLA-A*0201/TLADFDPRV tetramer
(EphA2-tetramer) were produced by the National Insti-
tute of Allergy and Infectious Disease tetramer facility
within the Emory University Vaccine Center (Atlanta, GA)
using the peptide synthesized by the University of Pitts-
burgh Peptide Production Facility. Cells were stained with
tetramers (10 µg/mL) in PBS containing 1% bovine serum
albumin for 15 minutes at room temperature, washed
once, and stained with fluorescein isothiocyanate (FITC)-
conjugated anti-human CD8 (BD Biosciences, San Diego,
CA). Flow cytometric analyses were done in the University
of Pittsburgh Cancer Institute (UPCI) Flow Cytometry
Facility on a DakoCytomation CyAN 9-Color High Speed
Analyzer using Dako Summit analysis program.
Four-color flow cytometry phenotype Analysis
PBMCs from the glioma patients were stained with several
different combinations of monoclonal antibodies that
have been used to delineate subsets of human memory/
effector CD8+ T cells. Each sample (2 × 106 PBMCs) was
stained with PE-conjugated EphA2-tetramer, FITC-conju-
gated anti-human CD8 (BD Biosciences), phycoerythrin-
cyanine 7-conjugated anti-human chemokine receptor
(CCR) 7 (BD Biosciences), and ECD-conjugated anti-
human CD45RA (BD Biosciences). After the addition of
the monoclonal antibodies, cells were incubated at 4°C
for 30 min, washed twice in staining buffer, and fixed in
500 µl of 1% paraformaldehyde. Cells were stored in the
dark at 4°C until analysis, which occurred within 24 h of
staining. All analyses were performed on four-color FACS
using Summit software (Dako Colorado, Inc. Fort Collins,
CO). Appropriate compensation and isotype controls
were run for all samples.Page 3 of 11
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To generate dendritic cells (DCs), the plastic adherent
PBMCs were cultured in AIM-V medium (Invitrogen) sup-
plemented with 1,000 units/mL recombinant human
granulocyte macrophage colony-stimulating factor and
500 units/mL recombinant human IL-4 (rhIL-4; Cell Sci-
ences) at 37°C in a humidified CO2 (5%) incubator. Six
days later, the immature DCs were stimulated with recom-
binant human tumor necrosis factor-α, IL-6, and IL-1β
(10 ng/mL each). Mature DCs were then harvested on day
8, resuspended in AIM-V medium at 1 × 106 per mL with
peptide (10 µg/mL), and incubated for 2 hours at 37°C.
Populations of autologous CD8+ T cells were enriched
from PBMCs using magnetic microbeads (Miltenyi Bio-
tech, Auburn, CA). CD8+ T cells (2 × 106 per well) were
cocultured with 2 × 105 per well peptide-pulsed DCs in 2
mL/well of AIM-V medium supplemented with 5%
human AB serum, 10 units/mL rhIL-2 (R&D Systems,
Minneapolis, MN), and 10 units/mL rhIL-7 (Cell Sci-
ences) in each well of 24-well tissue culture plates, Multi-
well Primaria (Falcon). On day 15, lymphocytes were
restimulated with autologous DCs pulsed with peptide in
AIM-V medium supplemented with 5% human AB serum,
rhIL-2, and rhIL-7 (10 units/mL each). On day 20, the
CD8+ cultured cells were analyzed for CTL activity by
standard 4-hour 51Cr release assay.
51Cr release cytotoxicity assay
Target cells (1 × 104 cells in 100 µl) labeled with 50 µCi of
Na51CrO4 (51Cr) were added to wells containing varying
numbers of effector cells (100 µl) using U-bottomed 96-
well plates. After 4 h incubation at 37°C, cells were centri-
fuged and 30 µl supernatant was collected and measured
for radioactivity. Percentage of specific lysis (% specific
lysis) was calculated as using triplicate samples follows:
percentage lysis = (cpm experimental release-cpm sponta-
neous release)/(cpm maximal release-cpm spontaneous
release) × 100.
Evaluation of leukocyte subsets in PBMCs
To obtain absolute lymphocyte counts (cells/µL) for each
desired lymphocyte subset, fresh peripheral blood sam-
ples were subjected to the Q-Prep/Prep Plus 2 system
(Beckman-Coulter). Monoclonal antibodies, CD3-FITC,
CD4-PC5, CD8-ECD, CD25-PE, and CD19-ECD, and iso-
type controls, IgG1-FITC, IgG2a-PE, and IgG1-ECD were
purchased from Beckman-Coulter. CD16-PC7 and CD56-
PC7, and isotype controls, IgG1-PC7 IgG2b-PC7 were pur-
chased from Becton-Dickinson.
After the cells were stained with these monoclonal anti-
bodies, "Flow Count" fluorospheres (Beckman-Coulter)
were added to each specimen using the Q-Prep/Prep Plus
2 for dispensing. These beads have a uniform size, fluores-
cence and concentration, allowing for direct measurement
of absolute counts. The lymphocytes were gated using for-
ward vs. side scatter, and each subset with specific pheno-
type was evaluated for both percentages of lymphocytes
analyzed and the absolute count. Expected normal con-
trol values were based on data with normal individuals.
Statistical analysis
Data are presented as means and standard deviation. Dif-
ferentiation status of EphA2-tetramer+/CD8+ T cells were
analyzed by one way analysis of variance for comparing
means of three or more variables, ANOVA.
Results
Expression of GAAs in the tumor derived from AA-1
We evaluated expression of IL-13Rα2 and EphA2 in tumor
tissues derived from the patient AA-1, as these GAAs
encode well characterized HLA-A2-restricted CTL epitopes
[18,19]. Immunohistochemical analyses of paraffin-
embedded specimens demonstrated a diffuse membra-
nous, partially cytoplasmic staining pattern in glioma
cells for both IL-13Rα2 and EphA2 (Figure 1A and 1B,
respectively). In contrast, negative control sections stained
without primary antibodies exhibited a negative or mini-
mal staining (Figure 1C).
In vitro stimulation of AA-1-derived PBMC induces potent 
GAA-specific CTLs
Expression of IL-13Rα 2 and EphA2 in the patient AA-1's
tumor led us to address whether antigen-specific T cell
response had been mounted in this patient. We first deter-
mined whether AA-1-derived PBMC could demonstrate
efficient antigen-specific CTL reactivity against IL-
13Rα2345–353 and EphA2883–891 following short-term in
vitro re-stimulation. PBMCs derived from three donors,
AA-1, GBM-1 and AO-1, were stimulated with autologous
DCs loaded with EphA2883–891 or IL-13Rα2345–353:1A9V and
evaluated for antigen-specific cytotoxic activity by 51Cr
release assays (Figure 2). AA-1 derived effector cells effi-
ciently lysed T2 cells pulsed with the relevant peptide, but
not control T2 cells pulsed with irrelevant M158–66 pep-
tide, demonstrating antigen-specific CTL activity of the
effector cells. Furthermore, these effector cells efficiently
lysed SNB19 human glioma cells that endogenously
express HLA-A2, EphA2 and IL-13Rα 2 [18,20]. In con-
trast, effector cells obtained from AO-1 and GBM-1 were
unable to lyse any of the target cells tested, except that
effector cells from AO-1 demonstrated a mild CTL activity
against IL-13Rα2345–353-pulsed T2 cells. These data sug-
gest that the patient AA-1 has mounted and maintained
CTL precursors that can exert antigen-specific CTL reactiv-
ity upon re-stimulation.Page 4 of 11
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reactive CD8+ cells derived from the glioma long term 
survivor
Efficient induction of the CTL response by in vitro re-stim-
ulation could reflect high numbers of naïve and/or mem-
ory GAA-specific CD8+ cells present in the patient AA-1's
PBMC. We therefore conducted flow cytometric analyses
of GAA-specific CD8+ cells in non-stimulated PBMC
derived from AA-1. Although we detected only back-
ground levels of CD8+ cells reactive to HLA-A*0201-IL-
13Rα2345–353:1A9V-tetramer [19], higher frequencies of
HLA-A*0201-EphA2883–891-tetramer+/CD8+ cells were
detected in PBMCs derived from the patient AA-1 com-
pared to those from the patient AO-1 and a healthy donor
(Figure 3). Although patient AO-1 exhibited the highest
frequency of IL-13Rα2-tetramer+/CD8+ cells compared to
two other donors, the CTL response following in vitro
stimulation was only modest against this epitope as
shown in Figure 2, suggesting a functional deficiency of
IL-13Rα2-reactive CD8+ cells in this patient.
We further examined differentiation phenotype of the
EphA2-tetramer+/CD8+ T cells based on the status of CC
chemokine receptor 7 (CCR7) and CD45RA [21]. Higher
percentages of central memory T cells (CD45RA-/CCR7+)
and effector memory T cells (CD45RA-/CCR7-) were
observed in EphA2-tetramer+/CD8+ T cells of AA-1 com-
pared to those of AO-1 and the healthy donor (P < 0.05;
ANOVA, Figure 4). On the other hand, there was a trend
towards lower numbers of naïve T cells (CD45RA+/
CCR7+) among EphA2-recognizing CD8+ cells in AA-1
compared to AO-1 and the healthy donor, although this
difference did not reach a statistical significance. These
results suggest that the long term survivor AA-1 may have
mounted an EphA2-specific CD8+ T cell response, and
that a majority of these cells had differentiated in vivo
towards antigen-experienced, central memory or effector
memory cells.
Elevated NK-T cell numbers in PBMC obtained from the 
patient AA-1
To characterize the frequencies of other immune cells in
the patient AA-1, we evaluated leukocyte subsets in whole
blood using T cell markers CD3, CD4, and CD8, a B-cell
marker (CD19), NK cell markers (CD16 and CD56) as
well as an activation marker CD25. Compared to the nor-
mal range obtained from normal donors, PBMC of AA-1
demonstrated elevated NK-T (CD3+/CD16+/CD56+) and
NK (CD3-/CD16+/CD56+) cell populations (Table 2),
suggesting a possibility that these innate immune effector
cells may have contributed to the long term anti-tumor
immune surveillance in this host. To eliminate concerns
over natural variation due to environment, this analysis
was repeated three times (at 2, 4 and 6 months following
the initial assay) with identical results.
Anaplastic astrocytoma of the glioma long term survivor (AA-1) expressed IL-13Rα 2 and EphA2Figure 1
Anaplastic astrocytoma of the glioma long term sur-
vivor (AA-1) expressed IL-13Rα 2 and EphA2. Paraffin-
embedded sections were stained with anti-human IL-13Rα 2 
polyclonal antibody (A), anti-EphA2 mAb (Ab208 mIgG1) (B), 
or without primary antibody (C) as described in Materials 
and Methods. Original magnification was × 20.Page 5 of 11
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In vitro stimulation of AA-1-derived PBMC efficiently induced GAA-specific CTLsFigure 2
In vitro stimulation of AA-1-derived PBMC efficiently induced GAA-specific CTLs. PBMCs derived from HLA-A2+ 
glioma patients, AA-1, AO-1, and GBM-1, were stimulated with autologous DCs loaded with IL-13Rα 2345–353:1A9V (A, C and E) 
or EphA2883–891(B, D and F). On day 20 after the primary stimulation, responder cells of AA-1 (A, B), AO-1 (C, D), and GBM-
1 (E, F) were tested for their lytic ability against human glioma cells SNB19 (Solid square, HLA-A2+, EphA2+, IL-13Rα 2+), or 
T2 cells loaded with IL-13Rα 21A9V (Solid circle in A, C and E), EphA2883–891 (Solid circle in B, D and F) or T2 cells loaded with 
Influenza M158–66 (hollow circle) using 4-hour 51Cr-release assays. Values indicate averages of duplicated samples, and represent 
data from one of two experiments with similar results. Bars indicate standard errors.
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AA-1 derived PBMC contained high numbers of EphA2883–891-tetramer+/CD8+cellsFigure 3
AA-1 derived PBMC contained high numbers of EphA2883–891-tetramer+/CD8+cells. Cryopreserved PBMCs derived 
from AA-1 (upper panels), AO-1 (middle panels), and an HLA-A2+ healthy donor (lower panels) were double-stained with 
FITC-conjugated anti-CD8 mAb and PE-conjugated IL-13Rα 21A9V-tetramer (left columns) or EphA2883–891-tetramer (right col-
umns). Cells sorted for CD8+ by flow cytometry are displayed. Numbers in each histogram indicate the percentage of 
tetramer-reactive cells among CD8+ cells. In three independent assays with AA-1-derived PBMC samples obtained at three 
separate time points spanning six months, the percentage of EphA2883–891-tetramer-reactive CD8+ cells was found to be 5% to 
10.5% in CD8+ PBMC.
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It has been well documented in immunogenic cancers,
such as melanoma [22-24], that cancer-bearing hosts can
spontaneously mount CTL responses against tumor asso-
ciated antigens detectable in peripheral blood and meta-
static nodes. It has also been suggested that naturally
occurring CTL responses may be associated with protec-
tion from tumor recurrence in melanoma long term survi-
vors [15,25]. However, in patients with malignant glioma,
to our knowledge, the current report is one of the first
evaluating a naturally occurring immune response, partic-
ularly an adaptive CD8+ T cell response against two well-
characterized GAA-epitopes. Wheeler et al. have demon-
strated that levels of CD8+ recent thymic emigrants
(RTEs), typically a tiny proportion of CD8+ T cells, consti-
tute the majority of tumor antigen-binding small precur-
sor cells in PBMC from GBM patients and account for the
prognostic power of age on clinical outcome in GBM
patients [26]. Even though our current study points to the
significance of antigen-experienced GAA-reactive cells, it
will be intriguing to evaluate RTEs in PBMC from the
patient AA-1.
The frequency of EphA2883–891-reactive CD8+ T cells in the
patient AA-1 was remarkably high (Figure 3). In other can-
cers, including melanoma [27], hepatocellular carcinoma
[28,29] and breast cancer [30], increased frequencies of
tetramer-reactive CD8+ cells have been reported,
although none of these studies found as high frequencies
of tetramer-reactive cells as found in our current study.
What is quite intriguing in these previous studies is that
they all suggest or indicate the presence of nonfunctional
tetramer+/CD8+ T cells in circulating PBMC. In our case,
comparable levels of antigen-specific CTL were induced
against both IL-13Rα 2 and EphA2 (Figure 2) despite
there were remarkably higher numbers of EphA2-
tetramer+/CD8+ cells than IL-13Rα 2-tetramer+/CD8+
cells, suggesting a possibility that EphA2-tetramer+/CD8+
cells have contained some nonfunctional cells.
Further characterization of EphA2883–891-reactive CD8+ T
cells revealed a majority of these cells are antigen-experi-
enced, which were skewed towards central memory or
effector memory cells (Figure 4). Given the fact that the
patient AA-1's tumor tissue expressed high levels of
EphA2, it is conceivable that tumor-expression of EphA2
has triggered activation of EphA2-reactive CD8+ precursor
cells, of which the majority remained as effector memory
and central memory T cells. It is noteworthy that central
memory tumor-reactive CD8+ T cells confer efficient and
Table 2: Lymphocyte populations in PBMC derived from AA-1
Counts (Number/µl)
<AA-1> <Normal range>
CD3+ (T cell) 1130.3 ± 193.4 912–1973
CD3+/CD4+ (CD4+ T cell) 799.7 ± 134.2 527–1376
CD3+/CD8+ (CD8+ T cell) 363.7 ± 65.6 290–604
CD3+/CD16+56+ (NK T cell) 175.7 ± 24.7 17–131
CD3-/CD16+56+ (NK cell) 276.3 ± 20.2 59–252
CD19+ (B cell) 242.3 ± 38.3 104–383
CD4+/CD25+ (Activated T cell) 182.3 ± 19.2 131 – 539
CD4+/CD25high+ 58.7 ± 18.7 31 – 115
A majority of EphA2883–891-reactive CD8+ cells in AA-1-derived PBMC are central m mory cellsFigure 4
A majority of EphA2883–891-reactive CD8+ cells in AA-
1-derived PBMC are central memory cells. Freshly 
thawed PBMCs were stained with anti-CD8 mAb, EphA2883–
891-tetramer, anti-CD45RA mAb, and anti-CCR7 mAb and 
analyzed as described in Materials and Methods. Black, gray 
and white columns indicate the percentage of each population 
in EphA2883–891-specific CD8+ cells derived from AA-1, AO-
1, and healthy donor, respectively. Bars indicate standard 
errors. Higher percentages of central memory T cells 
(CD45RA-/CCR7+) and effector memory T cells (CD45RA-/
CCR7-) were observed in EphA2-tetramer+/CD8+ T cells of 
AA-1 compared to those of AO-1 and the healthy donor (P < 
0.05; ANOVA).Page 8 of 11
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els [31,32]. It remains controversial, however, as to
whether maintenance of tumor-specific memory T cells
requires the presence of tumor-antigens in the host [33].
In the current study, patient AA-1 has not had a tumor-
recurrence for over 12 years. This does not exclude, how-
ever, a possibility that residual tumor cells still persist in
the host, and have provided the host immunity with a
source of antigen. Indeed, all malignant gliomas grow
invasively to the surrounding brain, and it is not consid-
ered possible to eliminate all tumor cells even if MRI scans
do not detect Gd-enhancing lesion in the brain of
patients. Nonetheless, our results suggest a possibility that
the high frequency of GAA-specific central memory T cells
may have contributed to the long term protection of the
patient AA-1 from tumor recurrence.
It would also be intriguing to delineate molecular mecha-
nisms underlying the antigen presentation against EphA2-
and IL-13Rα 2-derived epitopes in the patient AA-1 that
led to anti-tumor immunity instead of tolerance. Recently,
Apetoh et al. has shown that patients with Toll-like recep-
tor (TLR)-4 mutation do not mount a chemotherapy-
primed anti-tumor immune response, whereas intact TLR-
4 binds high mobility group box 1 (HMGB1), an early
mediator of inflammation, to activate DCs [34]. It would
be interesting to determine the status of TLR-4 in AA-1,
versus the other patients in this study.
The elevated NK-T (CD3+ CD16+ CD56+) and NK (CD3-
CD16+ CD56+) cell populations in the patient AA-1 (Table
2) suggest that these innate effector cells may also have
participated in the protection of tumor-recurrence in this
patient. However, we were unable to demonstrate a signif-
icantly superior cytotoxic activity of NK cells isolated from
the patient AA-1 compared to those isolated from two
other donors, GBM-1 and AO-1 (data not shown). Further
studies are warranted to evaluate the functional status of
NK-T cells in the patient AA-1 as NK-T cells can compose
an important part of anti-tumor host immunity [16].
In the current study, as controls for the samples from AA-
1, we tested PBMC from two other patients with malig-
nant glioma, both of which had recurrence of their tumors
and had received second-line chemotherapy by the time
their blood samples were drawn. One may raise a concern
as to whether our observations with the patient AA-1 are
significant because direct comparisons were made only
with these two other donors. In our previous studies with
PBMC samples from a total 42 patients with malignant
glioma [19], stimulation with the IL-13Rα 2 345–353:1a9V
peptide induced antigen-specific CTL responses in 18 of
42 (42.9%) cases. Interestingly, we could not detect any
statistically significant correlations between positive
responsiveness and clinical variables, such as patient age
(>50 or <50), type of glioma (glioblastoma multiforme
versus others), and prior or current treatment (i.e., chem-
otherapy). As we used identical stimulation conditions in
the current study, poor CTL responses observed in the two
direct control donors (GBM-1 and AO-1) may not repre-
sent results that would be expected in patients with malig-
nant glioma in general. Nevertheless, in these two patients
with histories of recurrences, low levels of EphA2-reactive
CD8+ T cells were associated with weak induction of GAA-
specific CTL responses, suggesting a possibility that
tetramer-based assessment of GAA-specific CTL precursors
may dictate the host-response to subsequent stimulations
with GAA, such as GAA-based vaccines.
Conclusion
Our data generated with blood and tumor samples from
patient AA-1 are highly valuable as it is uncommon to find
long term survivors with malignant glioma, especially
without recurrences for over 10 years [8]. The HLA-A2
haplotype allowed us to study GAA epitope-specific T cell
responses in this patient. Potent induction of CTL and
presence EphA2-specific memory CD8+ T cells observed in
the current study suggest that GAA-specific immunity may
serve as one critical surveillance mechanism against recur-
rence and progression of malignant glioma.
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